LO WILLIAM WING YAN DR 4
4 · Regencell Bioscience Holdings Ltd · Filed May 29, 2026
Research Summary
AI-generated summary of this filing
Regencell (RGC) Director William Lo Disposes 70,600 Options
What Happened Dr. William Wing Yan Lo, a director of Regencell Bioscience Holdings Ltd (RGC), reported a disposition to the issuer of options covering 70,600 ordinary shares on May 27, 2026. The company repurchased the options at $15.00 per option. The filing indicates the aggregate repurchase payment to Dr. Lo was reduced by the aggregate exercise price of the repurchased options (see footnotes).
Key Details
- Transaction date: May 27, 2026 (reported on Form 4 filed May 29, 2026). Transaction code: D (Disposition to issuer).
- Quantity: 70,600 options covering ordinary shares.
- Repurchase price: $15.00 per option (aggregate consideration further reduced by the options' aggregate exercise price).
- Derivative transaction: Yes — this was an option repurchase, not an open-market sale of underlying shares.
- Exercise-price adjustment: Footnote notes exercise price has been adjusted for any share splits since grant.
- Shares owned after transaction: Not specified in the filing.
- Filing timeliness: Report filed within two business days of the transaction (not indicated as late).
Context This was a derivative disposition (issuer repurchase of options). That means the company bought back option rights from the director; it does not necessarily reflect a sale of previously held underlying shares. The filing is factual and does not state the director’s motivation.
Insider Transaction Report
- Disposition to Issuer
Stock option (right to purchase)
[F1][F2]2026-05-27−70,600→ 521,630 totalExercise: $0.84→ Ordinary shares, par value $0.00001 (70,600 underlying)
Footnotes (2)
- [F1]The exercise price has given effect to the share split(s) of the Issuer since the date of grant of the option.
- [F2]On May 27, 2026, the Issuer repurchased from the Reporting Person options to purchase 70,600 ordinary shares of the Issuer at a price of $15.00 per option. The aggregate consideration payable to the Reporting Person under the Option Repurchase Agreement is further reduced by the aggregate exercise price of the repurchased options.